Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Specialized pro-resolving mediators (SPMs), including resolvins, protectins, and maresins, are bioactive lipid compounds derived from omega-3 and omega-6 fatty acids. They play a key role in actively resolving inflammation, rather than simply suppressing it. In the context of lupus (systemic lupus erythematosus or SLE), an autoimmune disease characterized by chronic inflammation and immune dysregulation, SPMs have been investigated in preclinical studies for their potential to modulate immune responses and promote resolution of inflammation. Animal studies and some in vitro experiments have demonstrated that SPMs can reduce inflammatory markers, decrease tissue damage, and potentially restore balance in immune cell populations in lupus models. For example, research in lupus-prone mice has shown that administration of certain SPMs leads to decreased kidney inflammation and improved survival rates. Mechanistically, SPMs appear to inhibit pro-inflammatory cytokine production and enhance the clearance of apoptotic cells, a process often impaired in lupus. However, robust clinical evidence in humans is lacking. There are currently no large-scale, controlled clinical trials demonstrating the efficacy of SPMs in treating lupus patients. Most data come from preclinical or early-phase research, and the translation of these findings to human disease remains uncertain. Thus, while there is scientific rationale and preliminary evidence supporting the use of SPMs in lupus, clinical validation is minimal, warranting a modest evidence rating.

More about specialized pro-resolving mediators (SPMs)
More about Lupus

Other ingredients used for Lupus

Other health conditions supported by specialized pro-resolving mediators (SPMs)

Products containing specialized pro-resolving mediators (SPMs)